$RMHI
Retrieve Medical Holdings, Inc.

2019 Q3 Form 10-K Financial Statement

#000119983522000814 Filed on December 19, 2022

View on sec.gov

Income Statement

Concept 2019 Q3 2019 2018 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.680K
YoY Change -79.58%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.684K
YoY Change -79.57%
Operating Profit -$5.684K
YoY Change -79.57%
Interest Expense $8.309K
YoY Change 48.8%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$13.99K
YoY Change -50.76%
Income Tax
% Of Pretax Income
Net Earnings -$13.99K
YoY Change -50.74%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$178.50
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $530.00
YoY Change -76.65%
Cash & Equivalents $0.00 $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $527.00 $530.00 $2.270K
YoY Change -76.78% -76.65% -24.11%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $527.00 $530.00 $2.270K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $527.00 $530.00 $2.270K
YoY Change -76.78% -76.65% -24.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $157.1K $157.1K $153.2K
YoY Change 2.57% 2.57% -6.07%
Accrued Expenses $15.50K $15.50K $7.186K
YoY Change 115.63% 115.58% -5.46%
Deferred Revenue
YoY Change
Short-Term Debt $20.00K
YoY Change 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $235.6K $192.6K $223.4K
YoY Change 5.48% 6.79% 14.15%
LONG-TERM LIABILITIES
Long-Term Debt $43.00K
YoY Change 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $43.00K
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $235.6K $192.6K $223.4K
Total Long-Term Liabilities $43.00K
Total Liabilities $235.6K $235.6K $223.4K
YoY Change 5.48% 5.48% 14.15%
SHAREHOLDERS EQUITY
Retained Earnings -$5.098M -$5.084M
YoY Change 0.28% 0.56%
Common Stock $7.836K $7.836K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$235.1K -$235.1K -$221.1K
YoY Change
Total Liabilities & Shareholders Equity $527.00 $530.00 $2.270K
YoY Change -76.78% -76.65% -24.11%

Cashflow Statement

Concept 2019 Q3 2019 2018 Q3
OPERATING ACTIVITIES
Net Income -$13.99K
YoY Change -50.74%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.743K
YoY Change -96.01%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$1.743K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -$1.743K
YoY Change 141.75%
FREE CASH FLOW
Cash From Operating Activities -$1.743K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78363567 shares
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78363567 shares
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Entity Registrant Name
EntityRegistrantName
PEAK PHARMACEUTICALS, INC.
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001452804
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78363567 shares
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78363567 shares
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018Q3 us-gaap Assets Current
AssetsCurrent
2270 usd
CY2019Q3 us-gaap Assets Current
AssetsCurrent
527 usd
CY2018Q3 us-gaap Assets
Assets
2270 usd
CY2019Q3 us-gaap Assets
Assets
527 usd
CY2018Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
20000 usd
CY2019Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
20000 usd
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
223362 usd
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
235612 usd
CY2018Q3 us-gaap Liabilities
Liabilities
223362 usd
CY2019Q3 us-gaap Liabilities
Liabilities
235612 usd
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
7836 usd
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
7836 usd
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4855566 usd
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4855566 usd
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5084494 usd
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5098487 usd
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2270 usd
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
527 usd
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-221092 usd
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-235085 usd
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
-192685 usd
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
153176 usd
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
157117 usd
CY2018Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
85062 usd
CY2019Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
87237 usd
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7186 usd
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15495 usd
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5684 usd
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27823 usd
CY2019 us-gaap Operating Expenses
OperatingExpenses
5684 usd
CY2018 us-gaap Operating Expenses
OperatingExpenses
27823 usd
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-5684 usd
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-27823 usd
CY2019 us-gaap Interest Expense
InterestExpense
8309 usd
CY2018 us-gaap Interest Expense
InterestExpense
5584 usd
CY2019 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-8309 usd
CY2018 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-584 usd
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-13993 usd
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-28407 usd
CY2018Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2270 usd
CY2019Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
527 usd
CY2017Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2991 usd
CY2019 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-1743 usd
CY2018 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-721 usd
CY2019 us-gaap Interest Paid
InterestPaid
usd
CY2018 us-gaap Interest Paid
InterestPaid
usd
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43000 usd
CY2019 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
43000 usd
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1743 usd
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43721 usd
CY2019 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
2175 usd
CY2018 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-14347 usd
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
usd
CY2018 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
5000 usd
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2019Q3 pkph Working Captial Deficiency
WorkingCaptialDeficiency
-235085 usd
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
.2100 pure
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100 pure
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0390 pure
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0390 pure
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3400 usd
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7100 usd
CY2019 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-3400 usd
CY2018 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-7100 usd
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-500 usd
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1100 usd
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2900 usd
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-6000 usd
CY2018Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
276000 usd
CY2019Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
279000 usd
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3291000 shares
CY2018Q3 us-gaap Cash
Cash
2270 usd
CY2019Q3 us-gaap Cash
Cash
527 usd
CY2019Q1 dei Entity Public Float
EntityPublicFloat
5944892 usd
CY2018Q3 us-gaap Notes Payable Current
NotesPayableCurrent
43000 usd
CY2019Q3 us-gaap Notes Payable Current
NotesPayableCurrent
43000 usd
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78363567 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78363567 shares
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2019 pkph Change In Fair Value Of Convertible Debt
ChangeInFairValueOfConvertibleDebt
usd
CY2018 pkph Change In Fair Value Of Convertible Debt
ChangeInFairValueOfConvertibleDebt
-5000 usd
CY2019 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
1252 usd
CY2018 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
12930 usd
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1766 usd
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4448 usd
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8309 usd
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-415 usd
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2745572 shares
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
236476 shares
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-.2490 pure
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0820 pure
CY2018Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
276000 usd
CY2019Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
279000 usd
CY2018Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
276000 usd
CY2019Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
279000 usd
CY2018Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2019Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2018Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1110000 usd
CY2019Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1124000 usd
CY2018Q3 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
-126000 usd
CY2019Q3 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
3000 usd
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
true
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2019 dei Entity File Number
EntityFileNumber
005-87668
CY2019 pkph Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Percent1
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent1
pure
CY2018 pkph Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Percent1
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent1
0.3310 pure
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Use of Estimates</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the&#160;consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Significant estimates made in connection with the accompanying consolidated financial statements include the valuation allowances against net deferred tax assets and accounting for convertible debt.</p>
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
133000 usd
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78363567 shares

Files In Submission

Name View Source Status
0001199835-22-000814-index-headers.html Edgar Link pending
0001199835-22-000814-index.html Edgar Link pending
0001199835-22-000814.txt Edgar Link pending
0001199835-22-000814-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
pkph-20190930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pkph-20190930_cal.xml Edgar Link unprocessable
pkph-20190930_def.xml Edgar Link unprocessable
pkph-20190930_lab.xml Edgar Link unprocessable
pkph-20190930.xml Edgar Link completed
pkph093019-10k.htm Edgar Link pending
pkph093019-ex31_1.htm Edgar Link pending
pkph093019-ex31_2.htm Edgar Link pending
pkph093019-ex32_1.htm Edgar Link pending
pkph093019-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pkph-20190930_pre.xml Edgar Link unprocessable